Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid

A Public Health Approach to Arthritis

Thomas R. Collins  |  March 12, 2020

ATLANTA—Rheumatic diseases have been the subject of a range of public health campaigns and reports over the past decade, but improving their visibility remains a work in progress, a Centers for Disease Control and Prevention (CDC) expert said at the 2019 ACR/ARP Annual Meeting. A growing attention to pain and the opioid crisis may help…

Filed under:AnalgesicsConditionsMeeting Reports Tagged with:2019 ACR/ARP Annual MeetingCenters for Disease Control and Preventionopioid crisisPain Managementpublic health

FDA Advisory Committees Reject Oxycodegol (NKTR-181) Application

Michele B. Kaufman, PharmD, BCGP  |  February 19, 2020

FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse…

Filed under:AnalgesicsDrug Updates Tagged with:FDANKTR-181opioidoxycodegolPain ManagementU.S. Food and Drug Administration (FDA)

A Public Health Approach to Arthritis: Experts Continue to Raise Awareness of Arthritis Burden

Thomas R. Collins  |  February 12, 2020

Public health agencies have been raising the profile of arthritis…

Filed under:Professional Topics Tagged with:ArthritisburdenCDCpublic health

New Gabapentinoid Warning Labels

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2020

Gabapentinoid products will now carry warning labels about the risks of respiratory distress when combined with opioids and other nervous system and respiratory depressants…

Filed under:Uncategorized Tagged with:Drug SafetyFDAgabapentinoidsU.S. Food and Drug Administration (FDA)

How to Work with Sales & Marketing Representatives in Your Practice

Steven M. Harris, Esq.  |  January 17, 2020

Sales and marketing representatives can add tremendous value to your practice: They can generate consistent business by leveraging contacts who have services that can be referred to your practice. However, the services a sales and marketing representative provides are subject to significant scrutiny under the federal Anti-Kickback Statute and state equivalents. For this reason, the…

Filed under:Legal UpdatesPractice Support Tagged with:Anti-Kickback StatuteEliminating Kickbacks in Recovery Act (EKRA)

The 2019 ACR Award Winners & Distinguished Fellows

Carol Patton  |  December 18, 2019

ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…

Filed under:AwardsFrom the CollegeProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingDr. Alfred E. DenioDr. Ali Duarte-GarciaDr. Amr H. SawalhaDr. Brian NolanDr. Bruce CronsteinDr. Dana DiRenzoDr. J. Timothy HarringtonDr. Jean LiewDr. John P. AtkinsonDr. Katherine P. LiaoDr. Marcy B. BolsterDr. Mazen NasrallahDr. Michael A. PaleyDr. Natalie RosenwasserDr. Patricia KatzDr. Polly FergusonDr. Rebecca HabermanDr. Sarah ChenDr. Susan ManziJonathan TL Cheah

Meet the Incoming Arthritis & Rheumatology Editor in Chief, Dr. Daniel Solomon

Kelly Tyrrell  |  December 18, 2019

Daniel Solomon, MD, MPH, has practiced rheumatology for more than 20 years, all while conducting translational and clinical research and teaching young clinicians. Soon, he will also step into the role of editor in chief of Arthritis & Rheumatology, as Richard J. Bucala, MD, PhD, ends his tenure. He will assume some duties during a…

Filed under:From the CollegeResearch Rheum Tagged with:Arthritis & RheumatologyDr. Daniel Solomon

On Boulders & Other Projects

Philip Seo, MD, MHS  |  December 18, 2019

The year is drawing to a close, and I have not been forced to release a statement that I am leaving The Rheumatologist “to spend more time with my family.” Once again, improbably, I have made it to the finish line. Given that, now seems to be a good time to reflect, and to give…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:American College of Rheumatology (ACR)

FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

Michele B. Kaufman, PharmD, BCGP  |  November 20, 2019

The FDA has limited the package size of some over-the-counter loperamide products to prevent its potential misuse and abuse…

Filed under:Biologics/DMARDsDrug Updates Tagged with:abuseBAT2506FDAGolimumabloperamideU.S. Food and Drug Administration (FDA)

Physical Activity Reduces Risk of Rheumatoid Arthritis

Lara C. Pullen, PhD  |  October 31, 2019

A recent study has taken a more detailed look at the relationship between physical activity and the risk of developing rheumatoid arthritis (RA). Researchers found the more patients exercised weekly the lower their overall risk, specifically brisk and very brisk walking paces, along with longer cumulative average walking hours weekly were associated with a reduced risk for RA…

Filed under:ConditionsRheumatoid Arthritis Tagged with:physical activityRheumatoid Arthritis (RA)walking

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences